Classical chemotherapy for metastatic melanoma (Q34067639)

30 July 2017

1 reference

title

Classical chemotherapy for metastatic melanoma (English)

1 reference

30 July 2017

1 reference

1 reference

Becker JC

1

1 reference

PubMed ID

11044186

30 July 2017

Kämpgen E

series ordinal

2

1 reference

PubMed ID

11044186

30 July 2017

Bröcker E

series ordinal

3

1 reference

30 July 2017

1 September 2000

1 reference

Clinical and Experimental Dermatology

30 July 2017

1 reference

30 July 2017

25

1 reference

30 July 2017

6

1 reference

30 July 2017

503-508

1 reference

New approaches to the systemic treatment of melanoma

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Prognostic parameters in uveal melanoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Fotemustine in the treatment of brain primary tumors and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00690.X

10.1046/J.1365-2230.2000.00690.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11044186